Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SOX as Adjuvant Therapy for Gastric Cancer
NCT07033143Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in gastric cancer (GC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT07033143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033143.